Back to search results

Study of AMG 513 for Obesity

This study is testing a new drug called AMG 513 for people with obesity. Researchers want to see how safe AMG 513 is and how well people tolerate it after receiving single or multiple doses. Some participants will receive AMG 513, while others will receive a placebo (an inactive substance). You might be able to join if you are 18 to 65 years old and have a body mass index (BMI) between 27.0 and 40.0 kg/m^2, depending on the study part. The study aims to enroll 80 participants. The current status of the study is unclear.

Study design
This study is testing AMG 513 against a placebo. It plans to enroll 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for treatment-emergent adverse events (side effects) for approximately 178 days in Part A and 225 days in Part B.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06585462

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Recruiting
PHASE1Ages 18–65InterventionalTreatment
Amgen
~80 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:AMG 513Placebo

At a glance

Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Measured over Approximately 178 days (Part A) and 225 days (Part B)

Conditions

Cardiometabolic Disease

Explore related trials

Cardiometabolic DiseaseObesity

Where it's being run

10 sites across 5 states
Florida4
California3
Georgia1
North Dakota1
Texas1

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

Amgen Call Center
[email protected]
866-572-6436
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) of 30.0 kg/m\^2 to 40.0 kg/m\^2 for Part A and BMI of 27.0 kg/m\^2 to 40.0 kg/m\^2 for Part B.
Females enrolled must be of non-childbearing potential.

Exclusion

History and/or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dL (7 mmol/L) at screening.
Triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL) at screening.

What this trial measures

  • Number of Participants With Treatment-emergent Adverse Events (TEAE)Approximately 178 days (Part A) and 225 days (Part B)